ESMO 2025: enhertu shows highest pCR rate in HER2+ early breast cancer
PositiveFinancial Markets

At the ESMO 2025 conference, the drug Enhertu has demonstrated the highest pathologic complete response (pCR) rate in patients with HER2-positive early breast cancer. This is significant as it highlights a promising advancement in treatment options for a challenging subtype of breast cancer, potentially improving outcomes for many patients.
— Curated by the World Pulse Now AI Editorial System